Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Too Old to Operate4d
Subgroup Analyses of Phase 3 Uproleselan Study in AML Encourages Further Exploration
Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...
Hosted on MSN27d
Daiichi Sankyo doses first subject in Phase III AML therapy trial
Arms A and B will compare the therapy and a placebo, both in conjunction with cytarabine and anthracycline induction, and cytarabine consolidation chemotherapy. This will be followed by up to ...
Medscape29d
Does Acalabrutinib Fit Into Frontline MCL Therapy?
However, treating patients with bendamustine/rituximab plus acalabrutinib might be preferred to either option with cytarabine. Although the results showed that the bendamustine/rituximab plus ...
Businessworld9d
kalyani open
INR:5777. kalyani open Can the medical representative registration system pull drug representatives back from sales to academia? The price of cytarabine has increase ...
Businessworld11d
pot of fortune pragmatic
INR:6609. pot of fortune pragmatic "Medical Speed ​​Reading Club" Shanghai Internet Hospital Management Measures will be implemented in September to ...